HIV vaccine: it may take two to tango, but no party time yet.

about

Vaccines for prevention of HIV infection Liposomes for HIV prophylaxis.Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.Levels of HIV1 gp120 3D B-cell epitopes mutability and variability: searching for possible vaccine epitopes.

P2860

Q24200691-1C277DFE-BA12-4392-BE88-54D2C02A5C9E Q35686901-0D5CEFDC-8E23-4855-AFA2-DFE089DFDF1B Q41923238-0A6E6095-3D42-42F8-8310-DA2C8B55CCF1 Q42961017-87914860-4F63-461B-9E16-D3979CA472B8

P2860

HIV vaccine: it may take two to tango, but no party time yet.

Item

http://www.wikidata.org/entity/Q42590256

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

HIV vaccine: it may take two to tango, but no party time yet.

@en

HIV vaccine: it may take two to tango, but no party time yet.

@nl

type

Item

label

HIV vaccine: it may take two to tango, but no party time yet.

@en

HIV vaccine: it may take two to tango, but no party time yet.

@nl

prefLabel

HIV vaccine: it may take two to tango, but no party time yet.

@en

HIV vaccine: it may take two to tango, but no party time yet.

@nl

P1476

HIV vaccine: it may take two to tango, but no party time yet.

@en

P2093

Ben Berkhout

http://www.w3.org/2001/XMLSchema#string

William A Paxton

http://www.w3.org/2001/XMLSchema#string

P2860

The aftermath of the Merck's HIV vaccine trial

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.

What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.

HIV vaccine design and the neutralizing antibody problem.

P2888

1742-4690-6-88

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1186/1742-4690-6-88

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26883895

http://www.w3.org/2001/XMLSchema#string

P6179

1012523786

http://www.w3.org/2001/XMLSchema#string

P698

19818121

http://www.w3.org/2001/XMLSchema#string

P932

2765936

http://www.w3.org/2001/XMLSchema#string

HIV vaccine: it may take two to tango, but no party time yet.

about

P2860

P2860

HIV vaccine: it may take two to tango, but no party time yet.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932